Table of Contents

Global Multivalent Vaccines Market Segment Research Report 2021

1. Research Scope

2. Market Overview

• 2.1 Product Introduction, Application, Picture
• 2.2 Global Multivalent Vaccines Market by Value
  • 2.2.1 Global Multivalent Vaccines Revenue by Type
  • 2.2.2 Global Multivalent Vaccines Market by Value (%)
• 2.3 Global Multivalent Vaccines Market by Production
  • 2.3.1 Global Multivalent Vaccines Production by Type
  • 2.3.2 Global Multivalent Vaccines Market by Production (%)

3. The Major Driver of Multivalent Vaccines Industry

• 3.1 Historical & Forecast Global Multivalent Vaccines Demand
• 3.2 Largest Application for Multivalent Vaccines (2017-2027)
• 3.3 The Major Downstream Company in China Market 2021

4. Global and Regional Multivalent Vaccines Market

• 4.1 Regional Market Size in Terms of Production & Demand (2021)
• 4.2 Regional Market Share in Terms of Revenue (2019-2027)
• 4.3 Concentration Ratio (CR5& CR10) of Multivalent Vaccines Market
• 4.4 Mergers & Acquisitions, Expansion Plans

5. US Multivalent Vaccines Production, Demand (2017-2027)

• 5.1 Current and Estimated Production Breakdown by Type
• 5.2 Current and Estimated Demand Breakdown by Type
• 5.3 Current and Estimated Demand Breakdown by Application
• 5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

6. Europe Multivalent Vaccines Production, Demand (2017-2027)

• 6.1 Current and Estimated Production Breakdown by Type
• 6.2 Current and Estimated Demand Breakdown by Type
• 6.3 Current and Estimated Demand Breakdown by Application
• 6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

7. China Multivalent Vaccines Production, Demand (2017-2027)

• 7.1 Current and Estimated Production Breakdown by Type
• 7.2 Current and Estimated Demand Breakdown by Type
• 7.3 Current and Estimated Demand Breakdown by Application
• 7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

8. Japan Multivalent Vaccines Production, Demand (2017-2027)

• 8.1 Current and Estimated Production Breakdown by Type
• 8.2 Current and Estimated Demand Breakdown by Type
• 8.3 Current and Estimated Demand Breakdown by Application
• 8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

9. India Multivalent Vaccines Production, Demand (2017-2027)

• 9.1 Current and Estimated Production Breakdown by Type
• 9.2 Current and Estimated Demand Breakdown by Type
• 9.3 Current and Estimated Demand Breakdown by Application
• 9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

10. Korea Multivalent Vaccines Production, Demand (2017-2027)

• 10.1 Current and Estimated Production Breakdown by Type
• 10.2 Current and Estimated Demand Breakdown by Type
• 10.3 Current and Estimated Demand Breakdown by Application
• 10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

11. Southeast Asia Multivalent Vaccines Production, Demand (2017-2027)

• 11.1 Current and Estimated Production Breakdown by Type
• 11.2 Current and Estimated Demand Breakdown by Type
• 11.3 Current and Estimated Demand Breakdown by Application
• 11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
• 11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

12. Global Multivalent Vaccines Average Price Trend

• 12.1 Market Price for Each Type of Multivalent Vaccines in US (2017-2021)
• 12.2 Market Price for Each Type of Multivalent Vaccines in Europe (2017-2021)
• 12.3 Market Price for Each Type of Multivalent Vaccines in China (2017-2021)
• 12.4 Market Price for Each Type of Multivalent Vaccines in Japan (2017-2021)
• 12.5 Market Price for Each Type of Multivalent Vaccines in India (2017-2021)
• 12.6 Market Price for Each Type of Multivalent Vaccines in Korea (2017-2021)
• 12.7 Market Price for Each Type of Multivalent Vaccines in Southeast Asia (2017-2021)

13. Industrial Chain (Impact of COVID-19)

• 13.1 Multivalent Vaccines Industrial Chain Analysis
• 13.2 Downstream
• 13.3 Impact of COVID-19
• 13.4 Technology Trends of Multivalent Vaccines

14. Multivalent Vaccines Competitive Landscape

• 14.1 GlaxoSmithKline, plc (U.K.)
  • 14.1.1 GlaxoSmithKline, plc (U.K.) Company Profiles
  • 14.1.2 GlaxoSmithKline, plc (U.K.) Product Introduction
  • 14.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.1.4 Strategic initiatives
• 14.2 Pfizer, Inc. (U.S.)
  • 14.2.1 Pfizer, Inc. (U.S.) Company Profiles
  • 14.2.2 Pfizer, Inc. (U.S.) Product Introduction
  • 14.2.3 Pfizer, Inc. (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.2.4 Strategic initiatives
• 14.3 Merck & Co., Inc. (U.S.)
  • 14.3.1 Merck & Co., Inc. (U.S.) Company Profiles
  • 14.3.2 Merck & Co., Inc. (U.S.) Product Introduction
  • 14.3.3 Merck & Co., Inc. (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.3.4 Strategic initiatives
• 14.4 Sanofi Pasteur SA (France)
  • 14.4.1 Sanofi Pasteur SA (France) Company Profiles
  • 14.4.2 Sanofi Pasteur SA (France) Product Introduction
  • 14.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.4.4 Strategic initiatives
• 14.5 Astellas Pharma Inc. (Japan)
  • 14.5.1 Astellas Pharma Inc. (Japan) Company Profiles
  • 14.5.2 Astellas Pharma Inc. (Japan) Product Introduction
  • 14.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.5.4 Strategic initiatives
• 14.6 CSL Limited (Australia)
  • 14.6.1 CSL Limited (Australia) Company Profiles
  • 14.6.2 CSL Limited (Australia) Product Introduction
  • 14.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.6.4 Strategic initiatives
• 14.7 Emergent BioSolutions, Inc. (U.S.)
  • 14.7.1 Emergent BioSolutions, Inc. (U.S.) Company Profiles
  • 14.7.2 Emergent BioSolutions, Inc. (U.S.) Product Introduction
  • 14.7.3 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.7.4 Strategic initiatives
• 14.8 Johnson & Johnson (U.S.)
  • 14.8.1 Johnson & Johnson (U.S.) Company Profiles
  • 14.8.2 Johnson & Johnson (U.S.) Product Introduction
  • 14.8.3 Johnson & Johnson (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.8.4 Strategic initiatives
• 14.9 MedImmune, LLC (U.S.)
  • 14.9.1 MedImmune, LLC (U.S.) Company Profiles
  • 14.9.2 MedImmune, LLC (U.S.) Product Introduction
  • 14.9.3 MedImmune, LLC (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.9.4 Strategic initiatives
• 14.10 Serum Institute of India Pvt. Ltd. (India)
  • 14.10.1 Serum Institute of India Pvt. Ltd. (India) Company Profiles
  • 14.10.2 Serum Institute of India Pvt. Ltd. (India) Product Introduction
  • 14.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue (2017-2021)
  • 14.10.4 Strategic initiatives
• 14.11 Bavarian Nordic (Denmark)
• 14.12 Mitsubishi Tanabe Pharma Corporation (Japan)
• 14.13 Daiichi Sankyo (Japan)
• 14.14 Protein Sciences Corporation (U.S.)
• 14.15 Panacea Biotec (India)

15. Conclusion

Summary

The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.

The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.

Regional Economic Prospects: Growth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.

The global Multivalent Vaccines market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to XYZResearch analysis, The segment in Multivalent Vaccines market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China Multivalent Vaccines production is XX (K Units). US market value in 2021 is about USD XX billion, and US Multivalent Vaccines production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe Multivalent Vaccines production is XX (K Units).

Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Multivalent Vaccines Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Multivalent Vaccines Market?
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc. (U.S.)
Johnson & Johnson (U.S.)
MedImmune, LLC (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (U.S.)
Panacea Biotec (India)
Major Type of Multivalent Vaccines Covered in XYZResearch report:
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Application Segments Covered in XYZResearch Market
Pediatrics
Adults

For any other requirements, please feel free to contact us and we will provide you customized report.